Status:

TERMINATED

NIV for COPD: Hospital to Home

Lead Sponsor:

San Francisco Veterans Affairs Medical Center

Collaborating Sponsors:

ResMed

Conditions:

Pulmonary Disease, Chronic Obstructive

Noninvasive Ventilation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This is a pilot study to evaluate the impact of providing patients admitted with acute exacerbations of COPD (AECOPD) with non-invasive ventilation (NIV)home devices prior to discharge on hospital rea...

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, with the economic and social burden of disease anticipated to increase annually. Acute exacerbatio...

Eligibility Criteria

Inclusion

  • Admission for acute hypercapnic respiratory failure requiring mechanical ventilation or NIV
  • Resolution of acute respiratory failure reflected by normalization of pH and downgrade of clinical status to ward or floor status.
  • Severe COPD defined by GOLD stage 3 (FEV1 30-50%) or 4 (FEV1 \< 30%) OR GOLD C or D. Pulmonary function tests (PFTs) done within 3 years preceding admission are acceptable to document an obstructive ventilatory defect and decrease diffusion capacity consistent with emphysema and COPD. If no PFTs are available, bedside spirometry will be performed to confirm COPD.
  • Chronic compensated respiratory acidosis based on PaCO2 \>52 adjusted for pH 7.40, on pre-admission laboratory values or after resolution of acute respiratory failure.
  • Able to consent without surrogate and complete all required study visits.

Exclusion

  • Moderate or severe obstructive sleep apnea (OSA), apnea-hypopnea index (AHI) \>15/h. Sleep testing done within the prior 3 years with no increase in body mass index (BMI) \>2kg/m2 or major change in cardiopulmonary conditions (new reduced ejection heart failure \[HFrEF\], atrial fibrillation \[AFib\], opioid use with morphine dose equivalent (MDDE) \>120mg, or cardiothoracic surgery for lung resection or coronary artery bypass grafting) will be accepted for AHI severity.
  • BMI\>35 kg/m2
  • Congestive heart failure (HFrEF, EF\< 45%)
  • Other cause of chronic respiratory failure: Obesity hypoventilation syndrome, spinal cord injury (cervical or thoracic) neuromuscular disease, diaphragmatic paralysis, chest wall restrictive ventilatory defect
  • Lack of stable housing, homelessness, or unreliable electricity source in home environment.
  • Use of NIV at home within past three months
  • Failure to tolerate NIV during initial hospitalization
  • Unable or unwilling to comply with the protocol
  • Age \<18 years
  • Inability to consent due to limited cognitive capacity
  • Pregnancy

Key Trial Info

Start Date :

May 9 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2024

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT04413643

Start Date

May 9 2019

End Date

April 1 2024

Last Update

April 25 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

San Francisco VA Health Care System

San Francisco, California, United States, 94121